Related Experiment Video
Updated: Aug 9, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Did the widespread use of long-acting calcium antagonists decrease the occurrence of variant angina?
Shozo Sueda1, Hiroaki Kohno, Hiroshi Fukuda
1Department of Cardiology, Saiseikai Saijo Hospital, Tsuitachi 269-1, Saijo City, Ehime Prefecture, Japan 793-0027. EZF03146@nifty.or.jp
Insights
Variant angina (VA) frequency has decreased, likely due to increased use of long-acting calcium antagonists (L-CAs). This study retrospectively examined VA cases, finding a significant decline in recent years.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Variant angina (VA) prevalence has appeared to decline with the widespread adoption of long-acting calcium antagonists (L-CAs).
- Retrospective analysis of VA frequency is crucial for understanding its current clinical significance.
Purpose of the Study:
- To investigate the changing frequency of variant angina (VA) over a 12-year period.
- To correlate observed trends with therapeutic interventions, particularly calcium antagonist use.
Main Methods:
- Retrospective analysis of 349 patients with angiographically confirmed coronary spastic angina (CSA) from 1991-2002.
- Classification of patients into four 3-year periods to assess temporal trends in VA and treatment modalities.
- Spasm provocation tests were used for diagnosis, with VA defined by ST elevation during attacks or stress tests.
Main Results:
- The overall ratio of VA to CSA significantly decreased over the study period (32% to 5%).
- While CSA diagnosis frequency remained stable, the number of VA cases and the VA/CSA ratio declined significantly in later years.
- Administration of L-CAs increased substantially in the latter half of the study, correlating with the decrease in VA.
Conclusions:
- The frequency of variant angina (VA) has demonstrably decreased in Japan.
- Widespread therapeutic use of long-acting calcium antagonists (L-CAs) is a likely contributing factor to this observed decline.
Background:
We have not often encountered variant angina (VA) since the use of long-acting calcium antagonists (L-CAs) became widespread.
Objectives:
This study examined the frequency of VA retrospectively.
Methods:
and results: We diagnosed angiographically confirmed coronary spastic angina (CSA) in 349 consecutive patients using selective spasm provocation tests from January 1991 to December 2002. During this period, 3,148 diagnostic cardiac catheterizations and 1,515 selective spasm provocation tests were performed. Seventy-four of these 349 patients (21.2%) had VA. Coronary spasms were defined as transient luminal narrowings of > 99%, and VA was defined as an ST elevation during spontaneous attacks or noninvasive stress tests. We classified the 12 years of the study into four periods of 3 years each. No tendency to decrease for the ratio of the number of patients with CSA and the number of selective spasm provocation tests was observed among the four time periods (18%, 24%, 32%, and 23%, respectively). However, the number of patients with VA (28, 33, 9, and 4) and the VA/CSA ratio (32%, 28%, 14%, and 5%, respectively) in the four group significantly decreased. The frequency of administration of calcium antagonists (CAs) before hospital admission (49% vs 33%, respectively; p < 0.05) was significantly higher in the last time period (from 2000 to 2002) than in the first period (from 1991 to 1993). L-CAs were administered in > 90% of CSA patients who had been medicated with CAs before hospital admission in the last period (from 2000 to 2002), while L-CAs were administered in only 20% in the former period (from 1991 to 1993). The administration of statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers before hospital admission gradually increased according to the period passed, but not significantly.
Conclusion:
The frequency of VA has decreased in Japan, possibly due to the widespread use of therapy with L-CAs.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification
Angina IV: Management

